Publications in collaboration with researchers from Hospital Universitari de Bellvitge (25)

2024

  1. Real-world Safety and Efficacy of Risankizumab in Psoriatic Patients: A Multicenter, Retrospective, and Not-interventional Study

    Actas Dermo-Sifiliograficas

  2. Recommendations from the Spanish Academy of Dermatology and Venereology Psoriasis Working Group on the Management of Patients with Cancer and Psoriasis

    Actas Dermo-Sifiliograficas

2023

  1. Apremilast treatment of plaque psoriasis (PsO) after systemic therapy in Spanish clinical practice: Data from the APPROPRIATE study

    JEADV Clinical Practice, Vol. 2, Núm. 3, pp. 488-501

  2. Selection of Quality Indicators for the Certification of Psoriasis Units: The CUDERMA Project Delphi Consensus Study

    Actas Dermo-Sifiliograficas, Vol. 114, Núm. 10, pp. 865-883

  3. Treatment of Severe Atopic Dermatitis With Upadacitinib in Clinical Practice: Short-Term Efficacy and Safety Results

    Journal of Investigational Allergology and Clinical Immunology

  4. Treatment of severe atopic dermatitis with tralokinumab in clinical practice: short-term effectiveness and safety results

    Clinical and experimental dermatology, Vol. 48, Núm. 9, pp. 991-997

2022

  1. Effectiveness and safety of guselkumab for the treatment of psoriasis in real-world settings at 24 weeks: A retrospective, observational, multicentre study by the Spanish Psoriasis Group

    Dermatologic Therapy, Vol. 35, Núm. 2

2021

  1. Food groups associated with immune-mediated inflammatory diseases: a Mendelian randomization and disease severity study

    European Journal of Clinical Nutrition, Vol. 75, Núm. 9, pp. 1368-1382

2020

  1. Current status of multidisciplinary care in psoriatic arthritis in Spain: NEXUS 2.0 project

    Reumatologia Clinica, Vol. 16, Núm. 1, pp. 24-31

  2. The effectiveness and safety of ixekizumab in psoriasis patients under clinical practice conditions: A Spanish multicentre retrospective study

    Dermatologic Therapy, Vol. 33, Núm. 6

2019

  1. Expert consensus on the persistence of biological treatments in moderate-to-severe psoriasis

    Journal of the European Academy of Dermatology and Venereology, Vol. 33, Núm. 7, pp. 1214-1223

  2. Genetic variation at the glycosaminoglycan metabolism pathway contributes to the risk of psoriatic arthritis but not psoriasis

    Annals of the Rheumatic Diseases, Vol. 78, Núm. 3, pp. 355-364

  3. Safety and effectiveness of conventional systemic therapy and biological drugs in patients with moderate to severe psoriasis and HIV infection: a retrospective multicenter study

    Journal of Dermatological Treatment, Vol. 30, Núm. 5, pp. 461-465

2018

  1. Management of Moderate to Severe Psoriasis in Routine Clinical Practice in Spanish Hospitals

    Actas Dermo-Sifiliograficas, Vol. 109, Núm. 7, pp. 631-642

  2. Standards of care and quality indicators for multidisciplinary care models for psoriatic arthritis in Spain

    Rheumatology International, Vol. 38, Núm. 6, pp. 1115-1124

2017

  1. Modelos de atención multidisciplinar en pacientes con artritis psoriásica en España

    Reumatologia Clinica, Vol. 13, Núm. 2, pp. 85-90

  2. Perception of psoriasis treatment in the outpatient setting: survey of patients and their prescribing physicians

    Journal of Dermatological Treatment, Vol. 28, Núm. 3, pp. 188-199

  3. Psoriasis moderada. Propuesta de definición

    Actas Dermo-Sifiliograficas, Vol. 108, Núm. 10, pp. 911-917

2016

  1. Development of clinical prediction models for good or bad response to classic systemic drugs, anti-TNFs, and ustekinumab in psoriasis, based on the BIOBADADERM cohort

    Journal of Dermatological Treatment, Vol. 27, Núm. 3, pp. 203-209

  2. Methotrexate in Moderate to Severe Psoriasis: Review of the Literature and Expert Recommendations

    Actas dermo-sifiliograficas, Vol. 107, Núm. 3, pp. 194-206